Targeting Cell Surface HIV Envelope for Cell Elimination (R01 Clinical Trial Not Allowed)
Posted by National Institutes of Health
Opportunity snapshot. This Grants.gov announcement — Targeting Cell Surface HIV Envelope for Cell Elimination (R01 Clinical Trial Not Allowed) — is cataloged under number PAR-25-300 and tied to CFDA assistance listing 93.855, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on December 2, 2024 and last updated on February 19, 2026. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Varies by applicant. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on February 19, 2026. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully — federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed — it helps clarify scope and scoring priorities.
Award Range
Varies by applicant
Close Date
February 19, 2026
Posted
December 2, 2024
Instrument
Grant
Description
The purpose of this notice of funding opportunity (NOFO) is to support the investigation of HIV-1 Envelope (Env) cell surface expression, the structural mechanism of biologic-mediated cell killing, and the development of novel approaches to enhance the recognition and elimination of Env-expressing, HIV-1 infected cells. These studies are expected to inform the development of immunotherapies and targeted vaccines for HIV-1 prevention and cure.
Eligibility
00;01;02;04;05;06;07;08;11;12;13;20;22;23;25
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Allergy, Immunology, and Transplantation Research
National Institutes of Health
Agency Contact
NIH Grants Information <br/>grantsinfo@nih.gov
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from National Institutes of Health
Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
Research Grants in Clinical Informatics (R01 Clinical Trial Optional)
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology — how this data is sourced, computed, and verified.
Related
| Publisher | Kiznis Studio |
| Sources | Public official public datasets |